University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

11-16-2009

Fatigue Symptom Distress and Its Relationship with Quality Of
Life in Adult Stem Cell Transplant Survivors
Suzan Fouad Abduljawad R.N., B.S.N.
University of South Florida

Follow this and additional works at: https://scholarcommons.usf.edu/etd
Part of the American Studies Commons

Scholar Commons Citation
Abduljawad, Suzan Fouad R.N., B.S.N., "Fatigue Symptom Distress and Its Relationship with Quality Of Life
in Adult Stem Cell Transplant Survivors" (2009). Graduate Theses and Dissertations.
https://scholarcommons.usf.edu/etd/1819

This Thesis is brought to you for free and open access by the Graduate School at Scholar Commons. It has been
accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons.
For more information, please contact scholarcommons@usf.edu.

Fatigue Symptom Distress and Its Relationship with Quality Of Life in Adult Stem
Cell Transplant Survivors

by

Suzan Fouad Abduljawad, R.N., B.S.N.

A thesis submitted in partial fulfilment
of the requirements for the degree of
Master of Science
College of Nursing
University of South Florida

Major Professor: Susan C. McMillan, Ph.D., A.R.N.P.
Cindy S. Tofthagen, Ph.D., A.R.N.P.
Brandy L. Lehman, Ph.D., R.N.

Date of Approval:
November 16, 2009

Keywords: cancer, adults, persistent fatigue, survivors, bone marrow transplant.
© Copyright 2009 , Suzan Fouad Abduljawad

DEDICATION
This thesis is dedicated to my outstanding mother, Khadija Elmoujarrad. Her
devotion, hard work, and thirst for knowledge inspired my motivation to pursue my
Master of Science degree, and the completion of this thesis. Thank you mother, your
endless love, support, prayers and encouragement put me on the road to success. To
my deceased father, Fouad Abduljawad, who had always encouraged me to learn and
dream big, I wish you were here to witness the success of your daughter getting the
honor of being the first female to attain the Master’s degree in the family. I would like
to also dedicate this thesis to my husband, Abdullah Wolkens, for his love, support,
and willingness to put my needs before his own. Thank you for believing in me. And
last but not least, I dedicate this to my beloved family. Grandmother Aicha El-Eidi
and Grandfather Jeloul Elmoujarrad, thank you for your unconditional love and your
continuous prayers; my brother Feras, who inspired me with his enthusiasm for higher
education and greater knowledge; my brother Fahad and sister Sundus, I appreciate
your love and encouragement, I hope you may find this thesis a source for your own
inspiration. I am blessed to have each and every one of you in my life.

ACKNOWLEDGMENTS
All Praises to Allah, Lord of the Universe, thank you for the strength that
keeps me standing and for the faith that brought light to my path and guided me. I am
forever in debt for your blessings with the people who have given their heart
whelming full support and encouragement in preparation of this thesis.
I would like to thank Dr. Susan McMillan, for the direction throughout this
project. I am short of words to express my gratitude for your guidance, your
encouragement, your tireless support, and above all because you had faith in my
success. I would also like to acknowledge my thesis committee members, Dr. Cindy
Tofthagen and Dr. Brandy Lehman for their time and contribution. I am extremely
grateful to Dr. Dee Dee Boyington for her invaluable help and support of my research
study. When new obstacles presented at every turn in the road to approval I was
blessed by having you help push it through. I am thankful to Doreen Appunn, MCC
Division of Research Compliance, for her great help and guidance. Many thanks to
Trudy Wittenberg USF unit research administrator, for helping me through my IRB
application. And finally, I am grateful to all the men and women who took part in my
study for seeing its value and taking the time to participate.

Table of Contents
List of Tables ............................................................................................................... iii
Abstract ........................................................................................................................ iv
Chapter I Introduction ....................................................................................................1
Statement of Problem .........................................................................................1
Research Questions ............................................................................................2
Definition of Terms............................................................................................2
Significance to Nursing......................................................................................3
Chapter II Review of Literature .....................................................................................5
Fatigue................................................................................................................5
Quality of Life..................................................................................................12
Summary ..........................................................................................................15
Chapter III Methods .....................................................................................................17
Setting and Sample ..........................................................................................17
Instrumentation ................................................................................................18
Cancer Related Fatigue Distress Scale (CRFDS) ................................18
Validity and Reliability ............................................................19
Functional Assessment of Cancer Therapy-Bone Marrow
Transplant (FACT-BMT)...............................................................19
Validity and Reliability ............................................................20
Demographic data Form ......................................................................20
Procedures ........................................................................................................21
Approvals .............................................................................................21
Data Collection ....................................................................................21
Data Analysis .......................................................................................22
Chapter IV Results, Discussion and Conclusions ........................................................24
Results ..............................................................................................................24
Sample..................................................................................................24
Fatigue Intensity and Symptom Distress .............................................26
Relationship between Fatigue Symptom Distress and QOL................28
Relationship between Fatigue Symptom Distress and Time from
Transplant ......................................................................................28
Relationship between QOL and Time from Transplant .......................28
Discussion ........................................................................................................29
Sample..................................................................................................29
Fatigue Symptom Distress and Quality of Life ...................................30
Relationship between Fatigue Symptom Distress and QOL................31
i

Relationship between Time from Transplant, Fatigue Symptom
Distress and QOL...........................................................................31
Conclusions ......................................................................................................32
Implications for Nursing ......................................................................32
Implications for Research ....................................................................33
References ....................................................................................................................34
Appendices ...................................................................................................................36
Appendix A: Cancer Related Fatigue Distress Scale (CRFDS) ......................37
Appendix B: Functional Assessment of Cancer Therapy–Bone Marrow
Transplant ..................................................................................................41
Appendix C: Demographic Data/Health History Information Form ...............44
Appendix D: Informed Consent .......................................................................45
Appendix E: Moffitt Cancer Center Scientific Review Committee approval .50
Appendix F: Institutional Review Board Approval .........................................52

ii

List of Tables
Table 1

Demographics and Clinical Characteristics of Patients .......................25

Table 2

Diagnoses and Type of Transplant ......................................................26

Table 3

Fatigue Intensity Score ........................................................................27

Table 4

Total Scores of CRFDS and FACT-BMT ...........................................28

Table 5

Pearson Correlation Coefficients between Fatigue Symptom
Distress, Quality of Life, and Time from Transplant...........................29

iii

Fatigue Symptom Distress and Its Relationship with Quality Of Life in Adult Stem
Cell Transplant Survivors

Suzan Fouad Abduljawad
ABSTRACT
Fatigue is a common problem among cancer patients, especially those who
have received chemotherapy and radiation therapy. Stem cell transplant (SCT)
patients are at a particular risk of persistent fatigue as they receive more aggressive
therapies. This study examined the prevalence of fatigue after completion of SCT.
Further, the level of fatigue symptom distress and its relationship with quality of life
(QOL) among long term SCT survivors was examined.
The study involved thirty-three patients, 21 males and 12 females, treated with
autologous or allogeneic SCT in a comprehensive cancer center in Southwest Florida.
Participants’ ages ranged from 36 to 70 years, with a mean age of 53 years. All
subjects completed the Cancer Related Fatigue Distress Scale and the Functional
Assessment of Cancer Therapy-Bone Marrow Transplant questionnaires. All the
patients had to be at least six months from transplant.
The results of this study showed that fatigue is quite prevalent among SCT
survivors. Ninety-three percent of the patients reported some degree of fatigue, and
15% experienced severe fatigue. Patients who received autologous transplant (24%)
reported less fatigue symptom distress (mean= 48, SD= 36.62) compared to the
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allogeneic transplant group (mean= 66.2, SD= 54.49). A strong negative relationship
was found between fatigue symptom distress and QOL (r = 0.85, p < 0.0001)
suggesting that patients with the greatest fatigue distress report the worst QOL. The
time from transplant factor was significantly positively associated with fatigue
symptom distress (r= 0.46, p= 0.007) indicating greater distress with the passage of
time. A moderate negative relationship was also found between time from transplant
and QOL (r= -0.34, p= 0.052) suggesting that QOL was less in some patients as time
passed; however this was a weak relationship that did not achieve statistical
significance.
Although the sample size was small, this study was able to provide a
confirmation that fatigue symptom distress and QOL are related to one another.
Understanding the relationship between fatigue symptom distress and QOL should
encourage interdisciplinary collaboration in planning proper interventions to minimize
fatigue. This would improve the outcomes of SCT long term survivors, and would
positively impact their overall QOL.

v

Chapter I
Introduction
Fatigue is a common symptom of cancer that has been demonstrated by
research to be one of the most distressing symptoms associated with cancer and all
cancer treatment modalities including chemotherapy, surgery, biotherapy, radiation
therapy, and bone marrow transplantation. It is reported that 70 to 100% of patients
who are undergoing cancer treatment suffer from fatigue at some or all stages of their
illness (Flude, Groll, Tranmen, & Woodend, 2007). This distressing symptom can
interfere with many aspects of QOL, including physical, psychosocial and spiritual
well being. Cancer patients undergoing stem cell transplant (SCT) are subject to
receiving high doses of chemotherapy and radiation therapy in bone marrow
conditioning regimens prior to transplant. The side effects from this multi-treatment
approach often precipitate heightened levels of fatigue (Gielissen et al., 2007).
Persistent burden on the physical and psychological status contributes to decreased
levels of activity, cognitive ability and the resultant poor sense of well being (Harder
et al., 2002). Certainly symptom management is a priority for those who strive to
improve patients’ outcomes. With growing evidence that SCT patients suffer from
persistent fatigue, it should be equally important for the clinicians and researchers to
understand this phenomenon and examine its relationship to QOL of SCT survivors.
Statement of the Problem
Fatigue is a common side effect that can be expected in the immediate
recovery period of SCT (El-Banna et al., 2004). When the transplantation journey
1

concludes, the patients hope to regain their pre-diagnosis health status, functional
ability, and their psychological, social and spiritual well being, to again lead their
lives somewhat normally. Unfortunately, some patients experience a lingering fatigue
that begins with their diagnosis of cancer, and continues in some cases for years after
the completion of successful therapy. However, the factors contributing to the
persistence of this problem and its impact on overall survival remains poorly
understood. Thus, this study sought to describe the phenomenon of persistent fatigue,
and how fatigue symptom distress is related to quality of life in long term SCT
survivors.
Research Questions
The following questions guided the study:
1.

What is the prevalence of fatigue and the level of fatigue symptom distress
reported by cancer patients at least six months past completing SCT?

2.

What do patients report their QOL to be at least six months after SCT?

3.

Is there a significant relationship between fatigue symptom distress and QOL of
cancer patients at least six months after SCT?

4.

Is there a significant relationship between fatigue and time from transplant?

5.

Is there a significant relationship between QOL and time from transplant?
Definition of Terms
For the purpose of this paper the following definitions are used.
Fatigue: An unusual, sustained, subjective sense of tiredness, malaise or lack

of energy, related to cancer or cancer treatment that interferes with usual functioning
(The National Comprehensive Cancer Network [NCCN], 2008).
Fatigue Symptom Distress: It is the distress and suffering that accompanies the
experience of the fatigue symptom (Holley, 2000).
2

Quality of life: Is a subjective multidimensional construct that represents
aspects of the individual’s satisfaction with well being. It is defined as the difference
or gap between the current hopes and expectation of the individual and that
individual's present experiences (Frick, Borasio, Zehentner, Fischer, & Bumeder
2004).
Stem cell transplantation: Is a procedure used to restore the stem cells when the
bone marrow has been destroyed by disease, radiation or chemotherapy. Depending
on the source of the stem cells, this procedure may be called a bone marrow transplant
(BMT), a peripheral blood stem cell transplant (PBSCT), or a cord blood transplant
(American Cancer Society, 2009).
Autologous stem cell transplantation (ASCT): A procedure in which bloodforming stem cells are harvested from the blood stream, stored, and later transfused
back to the same person (American Cancer Society, 2009).
Allogeneic stem cell transplantation (aSCT): A procedure in which a person
receives blood-forming stem cells from a genetically similar, but not identical, donor.
This is often a sister or brother, but could be an unrelated donor (American Cancer
Society, 2009).
Significance to Nursing
Describing the post transplant fatigue phenomenon is of particular significance
in improving SCT patients’ outcomes. In order to be able to design and achieve
optimal management of this distressing symptom, healthcare professionals need to
understand the magnitude of the problem. The knowledge of prevalence and severity
of fatigue reported by cancer patients after SCT, coupled with examining the quality
of life in relation to reports of the fatigue distress should help focus post transplant
nursing care. The information obtained from this study can assist nursing clinicians
3

and researchers, who strive to improve patients’ outcomes, in recognizing the impact
of fatigue on quality of life. This will further refine the clinicians’ timing of
supportive interventions and the content of education they provide to patients.

4

Chapter II
Review of Literature
This chapter presents the review of literature that is associated with fatigue and
the quality of life following SCT treatment in patients with hematologic malignancies.
First studies of fatigue are reviewed. This is followed by studies of quality of life, and
finally the literature is summarized.
Fatigue
In the past two decades, stem cell transplantation, following a conditioning
regimen of intensive high dose chemotherapy with or without total body irradiation,
has been used increasingly as means for a potential cure of many hematologic
diseases and malignancies (Hjermstad et al., 2004). This approach to treatment,
despite its effectiveness in decreasing mortality, is often complicated with unpleasant
symptoms and side effects that can be extremely daunting and at times even life
threatening.
The incidence and intensity of cancer related fatigue in BMT recipients varies
over the course of treatment and recovery. In a longitudinal study, El-Banna et al.
(2004) described the temporal patterns of depression and the four dimensions of
cancer related fatigue including: behavioral, sensory, cognitive and affective meaning.
Twenty-seven adult patients with lymphoma undergoing autologous stem cell
transplantation (ASCT) were included in this study. Fatigue was measured over
multiple time points; at baseline before chemotherapy initiation, on chemotherapy
day, and on recovery at days 2, 7, and 14. The authors used the revised Piper Fatigue
5

Scale (PFS), a multidimensional self-report fatigue instrument, on which high scores
indicate higher levels of perceived fatigue. El-Banna et al. (2004) found variations
over the two-week period following ASCT. The patients reported significant increase
of PFS scores from baseline to day seven for total fatigue and all dimensions of
fatigue except the cognitive or mood subscale. The pattern showed a decline after day
14 of transplantation. To measure depression, The Center for Epidemiologic Studies–
Depression (CES-D) Scale was used. Total scores on the CES-D scale range from
zero (no depression) to 60 (severe depression). A score of 16 or more on the CES-D
scale indicates depressive symptoms. The authors also found depression presenting a
similar pattern of sharp increase on day seven and a gradual decline afterwards with a
high positive correlation between affective fatigue and depression (p < 0.01). The
findings of this study highlight the importance of continuity of care, measuring
fatigue with concurrent assessment for depression, and paying close attention to the
immediate recovery period where the peak of these symptoms seems to occur.
From the NCCN definition of fatigue one can find the concept of fatigue
rendered with much influence on physical activity and functional ability. In a
prospective study, Hacker et al. (2006) sought to examine the feasibility of obtaining
real-time fatigue and physical activity data, to describe the patterns of fatigue,
physical activity, health status, and quality of life before and after hematopoietic stem
cell transplantation (HSCT). Twenty adult patients undergoing autologous or
allogeneic HSCT participated in the study. To assess fatigue, two different measures
were used, the fatigue subscale of the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC QLQ-C30) and
the Actiwatch (a wrist actigraph with a subjective event marker which was used as a
self report scale to measure real-time fatigue intensity). The Actiwatch was also used
6

to measure physical activity of the patients as the device consisted of an
accelerometer that records motion and speed of the subject.
The Quality of Life Index (QLI) was used to measure life satisfaction related
to the domains of family, health and functioning, social and economic, and
psychological or spirituality. The majority of the patients were found to experience
mild fatigue at baseline, which escalated following HSCT to significantly higher
levels (p<0.001). Also after HSCT physical activity markedly decreased by 58% and
overall health status became significantly worse. The significant decline in patients’
physical, emotional and cognitive functioning seemed to peak in the immediate posttransplant period. The authors also found this decline in functioning and physical
activity associated with significant increases in symptoms of fatigue, pain, nausea and
vomiting, diarrhea, loss of appetite and sleep disturbance. The QLI scores of
socioeconomic and psychological or spiritual subscales showed no significant
changes in this study, allowing the authors to support the notion that a lag time exists
between actual experiencing of health status changes and assimilating those changes
into an appraisal of life’s circumstances (Hacker et al., 2006). The study findings
suggest that patients experience prolonged fatigue and physical inactivity for at least 7
to 14 days following HSCT. This prolonged inactivity may eventually lead to
reduction of muscle mass and loss of strength and functional capacity. The
consequences of this diminished functional capacity are of particular concern with
patients’ ability to maintain or return to their productive roles in society (Hacker et al.,
2006). Therefore, maintaining levels of activity may enhance functional capacity and
role performance towards improving patient’s perception of health status and QOL.
This study further calls for effective management of fatigue symptoms experienced
during the immediate period following stem cell transplant.
7

An earlier study by Harder et al. (2002) considered fatigue a main disease and
treatment related predictor for cognitive impairment. Harder and colleagues examined
the cognitive functioning and quality of life in long-term adult survivors of bone
marrow transplant 22 to 82 months post treatment. The sample was comprised of 40
disease-free patients treated with SCT for hematological malignancies, 87% of whom
had undergone an allogeneic transplant. A battery of neuropsychological tests was
used to assess the mental status and cognitive performance of the subjects. For QOL
and mood states measurement the EORTC QLQ-C30 and the brief version of the
Profile of Mood States (POMS) were utilized. POMS measures five dimensions of
general psychological distress: depression, tension, anger, fatigue, and vigor. The
authors found mild to moderate cognitive impairment in 60% of the subjects,
especially in the areas of verbal learning, visual memory, selective attention and
information processing speed. A substantial correlation was found between cognitive
impairment and fatigue symptom on both EORTC QLQC30 (r= 0.55; p <0.001) and
POMS scales (r=0.51, p< 0.001). A significant relationship was also found between
fatigue, cognitive functioning and physical functioning. QOL and fatigue were
significantly associated with depression measured by POMS.
Fatigue remains a challenge for SCT patients even years after transplant. The
findings of this study indicate that fatigue can predict late cognitive deficits in long
term survivors. The authors reported that neuropsychological impairments and
cognitive complaints were associated with increased absence from work and school.
With such decreases in functional status, patients may experience role dissatisfaction
and a reduction in quality of life.
Clinicians mostly attribute fatigue to the nature of the cancer illness and the
treatment regimens. However, it is not well understood why fatigue persists long after
8

treatment completion when the patients are disease free or in complete remission
years after the transplant. Most recently in the Netherlands, Gielissen et al. (2007)
explored this phenomenon of post SCT persistent fatigue in light of the precipitating
and perpetuating theoretical model. The authors identified five perpetuating factors
that influence the persistence of fatigue symptoms which include insufficient coping,
fear of disease recurrence, cognitive dysfunction, sleep disturbance and dysregulation
of activity. In a cross-sectional retrospective design, ninety-eight survivals of acute
myeloid or lymphatic leukemia, chronic myeloid leukemia and non-Hodgkin’s
lymphoma who received autologous and allogeneic SCT between 1981 and 2003,
participated in the study. All patients had to be in persistent complete remission for at
least one year after SCT, those with graft-versus-host disease (GVHD) grade III and
IV or with hemoglobin of 10 g/dl and lower were excluded. This was done in order to
make the sample less prone to fatigue than the general population of SCT. Several
instruments were used to evaluate the prevalence of each of the perpetuating factors
identified. Fatigue was measured using the fatigue severity subscale of the Checklist
Individual Strength (CIS). A CIS fatigue score equal to or higher than 35 identified
severe fatigue. Even long after receiving SCT (mean= 9.3 years) thirty-four patients
(35%) met the criteria of severe fatigue and 12% had heightened fatigue scores. The
data analysis revealed a very low non-significant correlation between fatigue scores
and the length of hospital stay during transplantation. The correlation between CIS
fatigue scores and time since transplantation, which ranged from 1 to 15 years, also
proved to be low and non-significant. Patients with comorbidities such as
hypertension, diabetes, infections and hepatitis C were found to have higher levels of
fatigue (Gielissen et al., 2007). The authors also concluded that the perpetuating
model explained and highly predicted the severity and the persistence of fatigue,
9

suggesting that several psychosocial factors, rather than medical factors, were mostly
associated with persistent fatigue.
Anderson et al. (2007) assessed symptom burden of patients during the acute
phase of autologous transplant. The purpose of their study was to determine the
severity of the symptoms experienced by patients and to identify predictors of high
levels of symptom burden. The authors hypothesized that symptom intensity and
related interference would increase post transplant and be most severe at nadir. The
sample consisted of 100 patients with multiple myeloma or non-Hodgkin’s lymphoma
undergoing autologous stem cell transplantation with matched conditioning regimens
for each group. Assessment was carried out at baseline before commencing
conditioning regimen, on the third to fourth day of the conditioning regimen, on the
day of transplantation, on the day of nadir and on 30 days post-transplant. The
subjects were asked to complete the blood and marrow transplantation module of the
M. D. Anderson Symptom Inventory (MDASI-BMT), a measure of symptom severity
and symptom related interference in daily life, and the Eastern Cooperative Oncology
Group Performance Status (ECOG PS), which measures functional status, at each
time point. Mood and quality of life were measured on baseline and on day 30 posttransplant using the Profile of Mood States (POMS) and the Functional Assessment of
Cancer Therapy–Bone Marrow Transplant (FACT-BMT) scales (Anderson et al.,
2007). The authors reported that over half of the patients complained of moderate to
severe fatigue which interfered mostly with general activity, mood, walking, and
enjoyment of life. The mean scores of symptom severity and symptom interference
were significantly greater at nadir compared with baseline levels. Fatigue along with
symptoms of weakness, feeling physically sick, disturbed sleep, nausea and vomiting
showed the highest intensities. The severity of fatigue had a significant correlation
10

(p= 0.049) between the time point and the diagnosis. Patients with non-Hodgkin’s
lymphoma reported higher levels of fatigue at baseline, on nadir, and on 30 day posttransplant compared to the patients with multiple myeloma. Anderson et al. (2007)
related this difference among these two groups to differences in the disease
physiology or treatment history and conditioning regimens. Clinicians can help
optimize symptom management, as they become aware of the different symptoms’
burden and pattern associated with the different diagnoses of SCT population
(Anderson et al., 2007).
Another research study addressing the symptom burden by Bevans, Mitchell
and Marden (2008) was aimed at describing the symptom characteristics experienced
in the post transplant period. Seventy-six adult patients with hematologic disorders
undergoing their first matched related allogeneic SCT enrolled in this study. Data
were utilized from a prospective study of health-related quality of life (HRQL) in
which the participants were already enrolled. Symptom occurrence, distress, and
clusters were measured using the Symptom Distress Scale (SDS). Based on the 11
symptoms of nausea, appetite change, insomnia, pain, fatigue, bowel changes,
concentration, appearance, worry (outlook), breathing, and cough; each symptom is
rated on a 6-point Likert-type scale. Symptom distress was indicated as mild,
moderate, or severe. To be considered clustered, symptoms had to at least be
moderately and significantly related to one another and simultaneously independent of
other SDS symptoms (Bevans et al., 2008). Medical Outcomes Short Form 36 Health
Survey (SF-36 version 1) also was used to measure functional health and well being.
Data were collected on baseline before conditioning commencement and on days 0,
30, and 100 after allogeneic SCT. Bevans and colleagues reported that fatigue was
among the most prevalent symptoms across study time points. Fatigue was reported
11

by 68% of participants at baseline, 86% of participants on day zero, 90% of
participants on day 30 and 81% of participants at day 100 post-transplant. Fatigue
occurrence was also prevalent in symptom clusters. At baseline, the most prevalent
symptom cluster was fatigue and worry. On days 0 and 30 the symptom cluster
consisted of fatigue, bowel change, and insomnia. Fatigue symptom distress was
reported by six patients (11%) at day 100, but no symptom cluster was noted. The
authors suggested that the extent of symptom distress, prevalence, and occurrence of
fatigue in clusters emphasizes the importance of tailoring interventions to target
fatigue according to the phase of recovery. Fatigue symptom distress predicts poor
functional recovery, general health, and quality of life. Managing symptom distress
may provide SCT population with an opportunity for better outcomes (Bevans et al.,
2008).
Quality of Life
In a prospective study by Hjermstad et al. (2004), health related quality of life
(HRQOL), fatigue, anxiety, and depression were assessed in 248 patients with
hematological or lymphocytic malignancies, following treatment SCT. The purpose of
the study was to describe the fluctuations of those symptoms and HRQOL of the
patients over a period of three years or more after completion of transplant, while
comparing assessment scores between allogeneic SCT and autologous SCT groups
with patients who received conventional chemotherapy (CT) alone. The EORTC
QLQ-C30 questionnaire was utilized by the authors, is a 30-item tool which
incorporates five functional scales (physical, role, emotional, cognitive, and social); a
three symptom scales measuring fatigue, pain and nausea and vomiting; one scale
assessing overall health/global QOL; and six single items to assess symptoms
commonly reported by cancer patients such as dyspnea, sleep disturbances, appetite
12

loss, diarrhea, constipation and financial impact. The EORTC QLQ-C30 was
administered nine times throughout the three-year study period. Measurement of
physical and mental fatigue was assessed by the Fatigue Questionnaire (FQ). The FQ
asks questions about fatigue symptoms experienced during the last month compared
with how the subjects felt when they were well. Anxiety and depression symptom
distress was measured using the Hospital Anxiety and Depression Scale (HADS).
At baseline, a marked difference was found between allogeneic SCT and
autologous SCT patients on the fatigue symptom scale and global QOL scores. The
allogeneic SCT group experienced less fatigue and better quality of life at baseline,
but greater impairment than autologous SCT patients on second week post transplant
with an increase in fatigue symptoms and reduction in functional levels. Gradual
improvement in symptomatolgy occurred at 4 to 8 months until levels returned to
baseline at one year. In comparison, the autologous SCT group showed less
fluctuation from the baseline scores and a more rapid recovery, as global QOL scores
became similar to baseline or even better after four months only. The CT group
showed a negative change in global quality of life after 4 to 6 months of treatment,
where scores stabilized at a level significantly higher than baseline (Hjermstad et al.
2004).
The authors reported that despite that early recovery of the autologous SCT
group they were found to report poorer functioning and more fatigue at three years
after transplant. No statistically significant difference was reached for physical and
mental FS scores, yet more autologous SCT patients reported chronic fatigue when
compared to allogeneic SCT group, CT patients and the general population. There
was no significant change in depression or anxiety scores across all groups. The
authors also suggested that this pronounced impairment in QOL and the chronic
13

fatigue complaints of ASCT group, may be attributed to the extensive chemotherapy
and radiation those patients received prior to transplant. These findings emphasize the
importance of HRQOL assessment of stem cell transplantation recipients with focus
on functional status and fatigue symptoms. It is also important to advise patients to
maintain a close follow up with their health care providers to optimize the hospital to
home environment transition (Hjermstad et al. 2004).
Schulmeister, Quiett, and Mayer (2005) explored the quality of life, quality of
care, and patients’ satisfaction with outpatient autologous stem cell transplant (ASCT)
experience. Forty adult patients undergoing ASCT were interviewed via telephone,
three times, over a six-month period. To measure Quality of life, subjects were asked
to complete the Functional Assessment of Cancer Therapy–BMT (FACT-BMT) scale
during interviews at 4 to 6 weeks after chemotherapy and again at six months post
chemotherapy. The FACT-BMT scale measures five dimensions of QOL including:
physical, social/family, emotional, functional well-being, and BMT effects.
Telephone interviews guided by open-ended questions were used to explore patients’
ASCT experiences and satisfaction with the outpatient ASCT process (Schulmeister et
al., 2005). The authors found that patients who reported negative previous healthcare
experiences had significantly lower scores on the emotional well-being subscale.
Those who had progressive disease showed lower QOL and significantly more regret
for having the transplant. Concentration and memory problems, which interfered with
work, household responsibilities, leisure activities, and interpersonal relationships,
were experienced by 22% of the patients. FACT-BMT scores were lowest one month
post treatment and were highest six months post transplant. Higher QOL and greater
satisfaction with care were associated with good clinical outcomes following ASCT.
In general, the majority of the patients had reported a positive outpatient experience.
14

Although some of the patients reported that the outpatient ASCT experience did not
feel personalized, they complained that the recommendations for self care and
symptom management booklets, which they received in outpatient clinic, did not
address their personal concerns and needs. Many complained that important treatment
related issues such as: sexuality and fertility issues, complementary and alternative
therapies, and long term side effects were underemphasized. Patients expressed a need
for more information on how to maintain their strength and activity tolerance, fatigue,
and skin problems management. They also expected post transplant psychosocial
support to be offered for patients and families which could have further improved
their quality of life (Schulmeister et al., 2005).
One of the strengths of this study was that it included both qualitative and
quantitative research methods. The findings indicate the value of constructing
individualized interviews with patients where clinicians can personalize the
experience of SCT and address the most relevant concerns for each individual. The
SCT experience is faced with much uncertainty and thus, as these authors suggested,
the nurses should consider providing specific care plans including specific dietary
suggestions and exercise prescriptions. Ongoing evaluation of the survivors’ needs
and concerns would enhance patients’ satisfaction with the SCT experience and help
optimize the associated quality of life.
Summary
In summation, research has found that SCT related fatigue worsens in the
acute post transplant period along with the quality of life (El-Banna et al., 2004;
Hacker et al., 2006; Anderson et al., 2007). Many differing phenomena are associated
with fatigue in post SCT individuals. These phenomena could be physiological with
effects on strength, sleep pattern, and physical activity (Hjermstad et al., 2004), or
15

they could be cognitive, perceptual, motivational or psychological in nature (Harder et
al., 2002). Higher levels of fatigue symptoms distress have been predictive of poor
quality of life, poor general health, greater emotional distress, and overall mortality
(Gielissen et al., 2007; Schulmeister et al., 2005).
Proper assessment of the fatigue dimensions is essential in combating this
condition. Clinicians should be able to identify fatigue symptom distress in each
phase of recovery (Bevans et al., 2008) and design appropriate individualized
interventions with personalized patient education plans (Schulmeister et al., 2005).
Most of the available literature on fatigue in stem cell transplant population focused
on the acute recovery period. The current study is proposed to expand the knowledge
base related to fatigue intensity, fatigue symptom distress, and their relationship with
quality of life of long term adult survivors at least 5 months post stem cell
transplantation.
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Chapter III
Methods
This chapter presents the research methods and procedures that were used in
this study. First the sample selection and setting are described. Second, methods of
measurement including description of the Instruments with their validity and
reliability are discussed. Third, research procedures are described including the data
collection methods. Finally the data analysis plan is discussed. This descriptive,
exploratory study used a cross sectional design to describe the relationship between
fatigue symptom distress and quality of life (QOL) in stem cell transplant (SCT)
survivors.
Setting and Sample
The research data were collected at Moffitt Cancer Center, a National Cancer
Institute (NCI) designated comprehensive cancer center in southwest Florida. The
target population for this study was adult SCT survivors who were at least six months
following completion of SCT procedures including chemotherapy, total body
irradiation therapy and stem cells transfusion. Inclusion criteria included: (1) being an
adult over 18 years of age at the time of transplant, (2) incomplete or partial remission
of underlying disease, (3) being able to read and understand English, and (4)
willingness to participate in the study. Exclusion criteria for this sample included (1)
active cancer treatment with chemotherapy, radiation, or immunotherapy in the past 6
months, (2) hospitalization at the time of the study, (3) a history of chronic fatigue
syndrome, fibromyalgia, or any comorbidity related fatigue history, and (4) a current
17

psychiatric diagnosis or neurological deficit that may impede the subject’s ability to
comprehend the study. A sample of 50 adult BMT outpatients was sought.
Instrumentation
Three Instruments were used for this study, (1) The Cancer Related Fatigue
Distress Scale (CRFDS), (2) The Functional Assessment of Cancer Therapy-Bone
Marrow Transplant (FACT-BMT) version 4, and (3) a Demographic Data/Health
Information Form.
Cancer Related Fatigue Distress Scale
The Cancer Related Fatigue Distress Scale (CRFDS) was used to collect data
on fatigue symptom distress (Appendix A). The summated rating scale of 20 items
addresses cognitive, physical, psychological, social and spiritual distress The CRFDS
items have similar stem and response structure. Each item begins with: “The fatigue
or tiredness I am having causes me distress because it...” followed by an item from
distress categories (e.g., “Makes me too tired to eat “). The study participants were
asked to rate their distress on an 11-point scale, ranging from 0 (no distress) to 10
(severe distress). The CRFDS scores are based on how the subject has felt over the
last week, therefore, lending itself to a more accurate reporting of one’s overall
fatigue distress experience. The total possible scores of the scale ranges from zero to
200, the higher the score, the greater the level of fatigue symptom distress. The
CRFDS also includes three 0-10 fatigue intensity scales that measure "fatigue now"
"usual fatigue in the past week," and "worst fatigue in the past week.” Zero represents
no fatigue and ten as the most severe fatigue. The participants' performance status was
measured using the Karnofsky Performance Status (KPS) Scale, to determine the
participants' ability to perform daily activities (Holley, 2000).
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Validity and Reliability. The CRFDS has strong content validity and high
reliability. The items of this scale were constructed from 23 audio taped interviews
with 17 patients who experienced cancer related fatigue (CRF). Patients’ input in
developing the scale supported its construct validity. Factor analysis was used to
assess construct validity which confirmed all items loaded on one factor, indicating
that all items assessed CRF distress. Using a conservative standard of 0.70, 20 of the
23 items met the standard and were retained. Factor loadings ranged from 0.5890.913. The measure also has shown significant pre to post score changes (p <0.001).
Reliability for internal consistency estimate of this measure is very high, with
coefficient alpha of 0.98 (Holley, 2000).
Functional Assessment of Cancer Therapy–Bone Marrow Transplant
The Functional Assessment of Cancer Therapy–Bone Marrow Transplant
(FACT–BMT) is a 39-item scale that measures five dimensions of QOL in BMT
recipients including: physical (7 items), social/family (7 items), emotional (6 items),
functional (7 items) well-being and a 12 item BMT-subscale. BMT specific items
were designed to assess QOL content specific to the BMT process (Appendix B).
Patients are asked to rate themselves on how they feel today and over the past 7 days.
A 5-point Likert-type scale is used to rate each item of the questionnaire from 0 (not
at all) to 4 (very much). Higher scores are associated with higher levels of satisfaction
with QOL. The total scores for the FACT-BMT can range from 0–148. The FACTBMT was further expanded to include 23 items in the BMT subscale, resulting in
FACT-BMT (Version 4) which more specifically measures the unique effects of BMT
on QOL Items that were added to the subscale included ability to concentrate, ability
to remember things, experiencing blurry eyesight, experiencing frequent colds or
infections, noting food taste changes, having tremors, experiencing shortness of
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breath, having skin problems, experiencing bowel trouble, illness hardship on family
members, and the cost of treatment (McQuellon et al., 1997). These items are
considered experimental, with ongoing psychometric evaluation and currently are not
included in the scoring. This data was not reported. Respondent’s burden of this 50items scale is considered minimal as the average time to completion is 5-10 minutes
(McQuellon et al., 1997).
Validity and Reliability. The FACT-BMT underwent a three-step validation
process which involved testing of overall measures with subscales correlation and
internal consistency calculations. Items of BMT subscale were selected from a list
produced by seven oncology experts and 15 patients which enhances its construct
validity. The BMT subscale demonstrated sensitivity to change over time at baseline,
post-transplant, upon discharge and 100 days post transplant (McQuellon et al., 1997).
Coefficients of reliability and validity for the entire scale are high. The authors found
no significant difference between autologous or allogeneic SCT patients, or patients
with Graft Versus Host Disease (GVHD) compared to those without GVHD. This
supports more generalizability of this tool for the BMT population.
Demographic Data/Health Information form
Demographic and personal characteristics of the subjects were collected using
the Demographic Data/Health Information Form (Appendix C). The data included in
this form are: age, gender, ethnicity, educational background, marital status, and
employment status. Questions were asked about underlying cancer diagnosis, type of
transplant received and months from transplant completion, status of their cancer, and
whether they received any cancer treatment in the past 6 months. These data were
used to determine whether type of transplant and/or time from transplant influence the
experience of persistent fatigue.
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Procedures
Approvals
The principle investigator was responsible for assuring the research was
implemented safely and effectively in accordance with the regulations of the
Institutional Review Board (IRB) of the University of South Florida. Before obtaining
the research approval of IRB, a behavioral research application was filed with the
Scientific Review Committee of MCC. The benefit-risk ratio was assessed for this
study, indicating the study design had minimal risk to subjects and important benefits.
Informed consent (Appendix D) was designed to be easily understood and contained
no coercive language. Upon approval of MCC (Appendix E) the proposal was
submitted to IRB. Approval letter was obtained from IRB (Appendix F) along with
approved consent stamped with IRB approval and expiration date.
Data Collection
A research flyer was used to advertise the study and was distributed around
the BMT outpatient clinic, treatment center, and the clinic waiting areas at MCC. The
Principle investigator’s (PI) phone number was provided in the flyer for interested
individuals to contact and inquire about the study. The healthcare providers and
support staff of BMT clinic also identified potential participants, initiated the contact,
and referred them to the study. Upon visiting the outpatient clinic for scheduled BMT
follow up appointments, patients met with the PI and the study was explained. If
patients agreed to join the study, they completed a screening form which determined
their eligibility to participate.
The PI assessed potential participants using the inclusion/exclusion criteria.
When sample criteria were met, written consent to participate was collected from
patients and a copy of the signed informed consent was given to the participants to
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keep. Patients participating in other MCC fatigue or quality of life studies were not
asked to participate. Participants were taken to a private consult room, the study was
explained to them, and they were instructed on how to complete the three
questionnaires. Subjects were given the opportunity to ask questions about the
research and the PI was available in the area for clarification. Forms were reviewed
for completeness of response, staff and patients were thanked for their participation.
Data were gathered from 33 subjects. The raw data collected and original consent
forms were stored in a locked file drawer in the principle investigator’s locked office
and will be kept for five years after completion of study and then shredded.
Data Analysis
Descriptive statistics were performed for all variables. Tests were two-sided
and a p value of 0.05 or less was considered statistically significant. All data were
analyzed using the Statistical Package for Social Sciences (SPSS) for windows
version 18 software. Demographic data were reported with frequencies, percentages,
means, standard deviations, and ranges; which are presented in the sample
characteristics table (Table 1).
The research questions provided direction for this data analysis. For research
question #1: What is the prevalence of fatigue and the level of fatigue symptom
distress reported by cancer patients at least six months past completing SCT? The
mean ratings of each item on the CRFDS were used to evaluate the levels of fatigue
Intensity and fatigue distress described by the participants.
Similarly, for research question #2: What do patients report their quality of life
to be at least six months after SCT? Mean quality of life scores of FACT-BMT were
calculated overall and among subscales.
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For research question #3: Is there a significant relationship between fatigue
symptom distress and quality of life of cancer patients at least six months after SCT?
Pearson’s correlation coefficient (r) was utilized.
Similarly, for research questions 4 and 5, the Pearson correlation was used to
assess the association between time from transplant and fatigue symptom distress and
quality of life.
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Chapter IV
Results, Discussion and Conclusion
The following chapter presents the findings of this study. First, the sample is
described. Next, the research questions are addressed. The results, strengths and
limitations of the study are discussed. The chapter also includes recommendations for
nursing practice, nursing education, and nursing research.
Results
Sample
Thirty- nine (n = 39) BMT outpatients were approached to participate in the
study. Four declined participation due to feeling tired, and thirty-five (n = 35) agreed
to participate. Two of the completed questionnaires were discarded for incomplete
information. Twenty-one males and 12 females participated in this study (N = 33)
(Table 1). The mean age was 53 (SD = 9.79) with a range between 36 and 70 years.
Of the 33 participants, 24 (73%) were married, 5 (15%) were single, 3 (9%) were
divorced, and 1 (3%) was widowed. A majority of the patients were Caucasian (79%),
followed by Hispanic (15%), and African American (6%). Seventy-six percent (n =
25) of the recipients received allogeneic stem cell transplantation and the remainder
underwent autologous SCT (n = 8). The mean length of time from transplant for
surviving patients was 19.24 months (SD = 17.78; range = 6–84 months, n = 33).
Among the participants the most frequently occurring diagnoses were non Hodgkin’s
lymphoma (24%), followed by acute myeloid leukemia (21%), and acute lymphocytic
leukemia (18%) (Table 2).
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Table 1
Demographics and Clinical Characteristics of Patients
Variable

Frequency

Percentages

Male

21

64

Female

12

36

Caucasian

26

79

Hispanic

5

15

African American

2

6

0–11

2

6

High school

10

30

Some college

11

33

College graduate

8

24

Post graduate

2

6

Married

24

73

Single

5

15

Separated/divorced

3

9

Widowed

1

3

Disability/unemployed

15

45.4

Employed

13

39.4

Retired

5

15.2

Gender

Race/ethnicity

Education

Marital status

Occupational status
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Table 2
Diagnoses and Type of Transplant
Variable

Frequency

Percentages

Non-Hodgkin lymphoma

8

24.2

Acute myeloid leukemia

7

21.2

Acute lymphocytic leukemia

6

18.2

Multiple myeloma

5

15.2

Myelodysplastic syndromes

3

9.2

Chronic lymphocytic leukemia.

1

3

Chronic myeloid fibrosis

1

3

Chronic myeloid leukemia

1

3

Small Cell Lung Carcinoma

1

3

Allogeneic

25

76

Autologous

8

24

Diagnosis

Type of transplant

Fatigue Intensity and Symptom Distress
Research question 1: What is the prevalence and level of fatigue distress
reported by cancer patients at least six months past completing SCT? Thirty-one
participants (93.9%) reported persistent fatigue and five (15%) rated their fatigue 10
out of 10 at its worst. The mean value of current fatigue reported by allogeneic
transplant participants was 2.56 (SD= 2.33), and mean= 2.38 (SD= 1.69) for the
autologous transplant subjects, for both groups combined the mean was 2.52 (SD=
2.17). The mean usual fatigue of all participants was 2.85 (SD= 1.97), for allogeneic
transplant participants the mean usual fatigue was 2.84 (SD= 2.07) and 2.88 (SD=
1.73) for autologous transplant participants. The mean worst fatigue for all subjects
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was 4.79 (SD= 3.07), 4.56 (SD= 3.09) for allogeneic transplant participants and 5.50
(SD= 3.07) for autologous transplant participants (Table 3). The ratings of CRFDS
were summed for each participant, the total scores ranged from 0–195, with a mean
value of 61.8 (Table 4).
Table 3
Means, Standard Deviations and Ranges of Fatigue Intensity Scores
Variable

n

Minimum

Maximum

Mean

SD

33

50

100

85

13.5

Usual

33

0

7

2.85

1.97

Current

33

0

8

2.52

2.17

Worst

33

0

10

4.79

3.07

KPS scale
Total Fatigue intensity

Allogeneic
Usual

25

2.84

2.07

Current

25

2.56

2.33

Worst

25

4.52

3.09

Usual

8

2.38

1.69

Current

8

2.88

1.73

Worst

8

5.50

3.07

Autologous

Note. n= number of subjects, SD= Standard Deviation.

Research question 2: What do patients report their quality of life to be at least
six months after SCT? Total scores of the FACT-BMT ranged from a minimum of 57
and a maximum of 145 with the mean of 113.78 (Table 4).
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Table 4
Means, Standard Deviations, and Ranges of Total Scores of CRFDS and FACT-BMT
n

Minimum

Maximum

Mean

SD

CRFDS total

33

0

169

61.89

50.82

FACTBMT total

33

57

145

113.78

25.66

Relationship between Fatigue Symptom Distress and QOL
Research question 3: Is there a significant relationship between fatigue
symptom distress and quality of life of cancer patients at least six months after SCT?
Pearson’s product-moment correlation coefficient (r) was used to calculate the
relationship between the total scores of fatigue symptom distress levels from CRFDS
and the total scores of QOL from FACT-BMT. A strong negative correlation (r= -.86,
p <.0001) was found, which was statistically significant (Table 5).
Relationship between Fatigue Symptom Distress and Time from Transplant
Research question 4: Is there a significant relationship between fatigue and
time from transplant? To assess the association between time from transplant and
fatigue symptom distress, Pearson’s product-moment correlation coefficient (r) was
used. A moderate positive relationship was found between CRFDS total and the time
from transplant (r= .46, p= .007). This finding was statistically significant (Table 5).
Relationship between QOL and Time from Transplant
Research question 5: Is there a significant relationship between quality of life
and time from transplant? The Pearson correlation coefficient was used to examine
the relationship between QOL and time from transplant. A moderate negative
correlation was found (r= -.34, p=.052) which did not reach statistical significance
(Table 5).
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Table 5
Pearson Correlation Coefficients between Fatigue Symptom Distress, Quality of Life, and
Time from Transplant
Fatigue Symptom Distress

Quality of Life

Variable
n

r

Quality of life

33

-.86

Time from Transplant

33

.46

p

n

r

p

<.0001

33

1

___

.007

33

-.34

.052

Discussion
Sample
In this study, a convenience sample of 33 men and women was accrued at the
comprehensive cancer center MCC. When the participants came to the BMT clinic
for post transplant follow up visits they met with the PI and completed the consent
form meeting all institutional, state, and federal guidelines. They also completed the
CRFDS and FACT-BMT with an attached demographic data form. The tools took
approximately 20 minutes to complete. A minimal respondents’ burden is of a
particular importance when measuring fatigue in individuals who may already have
attentional deficits, lack of energy, and feelings of tiredness.
A limitation of the sample is that it did not represent the SCT types accurately
for the BMT population. The majority of the participants underwent allogeneic stem
cell transplant, and only eight of them had autologous SCT. In addition, although
participation criteria were nonexclusive of ethnicity groups or racial backgrounds,
minorities were not well represented in this sample. There were also more men than
women participants. Strength of the sample is the diversity of the underlying
diagnosis which included eight different types of cancer, which is a good
representation of the SCT population.
29

Fatigue, Symptom Distress, and Quality of Life
This study identified that fatigue is widely prevalent among BMT long term
survivors; approximately 93% of the subjects experience some degree of fatigue
according to the fatigue intensity scale of CRFDS. The literature reviewed in this
study supports this finding. Gielissen et al. (2007) reported that side effects of BMT
often precipitate heightened levels of fatigue. In this study, 5 participants (15%) rated
their fatigue 10 out of 10 at its worst. This finding is in agreement with the
assumption that patients with more aggressive treatments such as BMT are more at
risk for persistent fatigue. The CRFDS total scores ranged from 0–195, with a mean
of 61.8. The mean of fatigue symptom distress is considered somewhat low. A
possible explanation for the inconsistency between the literature reviewed and this
study finding is the diversity of underlying diagnoses and the difference in the type of
BMT. Also, it should be considered that CRFDS measures the distress and suffering
that accompanies the experience of fatigue symptom. Although fatigue symptom was
quite prevalent among the participants, fatigue intensity can occur in variable levels
that are not necessarily altogether distressful.
In this study, the majority of patients (76%) received allogeneic SCT. Those
who received autologous transplant (24%) reported less fatigue symptom distress
with mean= 48.0 (SD= 36.62), compared to the allogeneic transplant group (mean=
66.2, SD= 54.49). Although this difference did not reach statistical significance (p=
0.71) it is considered clinically significant. A possible explanation of this difference is
that autologous SCT patients underwent a shorter hospital stay during transplant, had
fewer complications and had no risk for GVHD compared to allogeneic transplant
patients. In this sample of patients it was also found that fatigue symptom distress in
allogeneic transplant subjects have been more severe. Harder et al. (2007) also related
30

that to their exposure to acute and chronic GVHD and other complications related to
immunosuppression or immunosuppressive therapy. However, this finding should not
distract from the fact that some autologous transplant participants did report fatigue
symptom distress which should still be addressed on individual bases.
The total FACT-BMT scores ranged from 57-145. The mean score was
113.78. This study found moderate levels of QOL. Schulmeister, Quiett and Mayer
(2005) reported that higher QOL and greater satisfaction were associated with good
clinical outcomes following transplant though there were lingering fatigue effects.
Gielissen et al. (2007) also reported that fatigue persists long after treatment had
ended.
Relationship between Fatigue Symptom Distress and QOL
A strong significant negative correlation (r= -.85, p <.0001) was found
between reported levels of fatigue symptom distress and QOL in this sample. The
greater the levels of fatigue symptom distress, the poorer the quality of life. This
negative correlation was an expected finding, and it supports the idea that persistent
fatigue has a detrimental consequence on QOL of BMT long term survivors.
However, a correlational study does not confirm cause and effect. This study supports
the findings of Hjermstad et al. (2004) who reported an inverse relationship between
fatigue, cognitive or social function and QOL.
Relationship between Time from Transplant, Fatigue Symptom Distress and QOL
A significant moderate positive correlation was found between CRFDS total
scores and the time from transplant (r= .46, p= .007). This correlation may be
precipitated by emotional rather than physical distress; that is, those who had the
longest survival seemed more distressed by fatigue. This relationship may occur
because they expected a resolution of their symptoms and a sooner return to
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normalcy. For patients closer to the time of transplant, there is reason to be hopeful
that fatigue symptoms will fade away when they return to their normal functional
levels and regain their full strength.
A moderate negative relationship was found between QOL and time from
transplant, supporting the idea that lingering fatigue does affect the quality of life.
Although a shorter time from transplant correlated with higher QOL levels (r= -.34,
p=.052) this finding did not reach statistical significance. It should also be noted that
the most well-functioning transplant patients completed the questionnaires, while the
most ill, most fatigued patients declined participation. Approximately 10% of these
patients stated upon request that they did not feel well, they felt tired, and that was
why they did not want to take part in the study. The failure of these patients to
participate might have biased the study results in some important ways.
Conclusions
Implications for Nursing
This study supports the importance of addressing fatigue symptoms in patients
who have undergone BMT as a possible approach to improving overall QOL. The
study findings reflect that approximately 93% of the participants in this study
experience some degree of fatigue after transplant. Also, it demonstrated a significant
negative relationship between fatigue symptom distress and quality of life. This is
relevant to nursing care and patient education. It would be highly advisable to inform
the patients prior to transplant of the potential of developing some persistent fatigue
that they may find to be distressing. The consequences of this can be diminished
functional capacity which is of particular concern with patients’ ability to maintain or
return to their productive roles in society (Hacker et al. 2006). Therefore, it is equally
important to maintain levels of activity to enhance functional capacity and role
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performance towards improving patient’s perception of health status and QOL.
Understanding the relationship between fatigue symptom distress and QOL should
encourage interdisciplinary collaboration in planning proper interventions to minimize
fatigue. This would improve the outcomes of BMT long term survivors and would
positively impact their overall quality of life.
Implications for Research
A limitation of this study is that the patients with the worst BMT experience
probably were not accessible because of their fatigue. Future studies with larger
sample size should evaluate the specific chemotherapeutic agents or dosages used in
BMT conditioning protocols and determine whether they impact the occurrence,
frequency and persistence of fatigue. Similarly, the cross sectional design of this
study lacks pre-treatment baseline assessment which precludes definite conclusions
about a change in fatigue and QOL over time. A longitudinal cohort study using a
comprehensive psychosocial test to investigate the effects of BMT treatment on the
QOL of adult long term survivors is warranted.
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Appendix A: Cancer Related Fatigue Distress Scale (CRFDS)
CANCER RELATED FATIGUE DISTRESS SCALE
(CRFDS)
Sandra Holley, PhD, ARNP
Instruction:
Below and on the next 3 pages is a list of problems people sometimes have because of
their cancer related fatigue. Please read each one carefully. Please circle the number
that best describes HOW MUCH THAT PROBLEM HAS DISTRESSED OR
BOTHERED YOU DURING THE PAST 7 DAYS, INCLUDING TODAY. Circle
only one number for each problem and do not skip any items. If you change your
mind, erase your first mark carefully. Read the example before beginning, and if you
have any questions please ask them now.
Please complete all 20 items and the 3 additional items on the last page.
The fatigue or tiredness I am having causes me distress because it:
1. Makes it difficult for me to concentrate.
How much distress does this cause you?
0
No distress

1

2

3

4

5

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

8

9
10
Severe distress

8

9
10
Severe distress

2. Makes me feel that I must accept more help from others.
How much distress does this cause you?
0
No distress

1

2

3

4

5

3. Makes me feel that I am more than just tired.
How much distress does this cause you?
0
No distress

1

2

3

4

5

4. Makes me feel frustrated when I can’t do what I used to do.
How much distress does this cause you?
0
No distress

1

2

3

4

5

6

7

5. Makes my body feel as though it doesn’t want to function.
How much distress does this cause you?
0
No distress

1

2

3

4

5
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Appendix A (Continued)
The fatigue or tiredness I am having causes me distress because it:
6.

Makes it difficult for me to form whole thoughts.
How much distress does this cause you?

0
No distress
7.

1

2

3

4

5

6

7

8

9
10
Severe distress

Makes me feel like my physical abilities are being worn away.
How much distress does this cause you?

0
No distress
8.

1

2

3

4

5

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

Makes me feel that I am still tired after sleeping.
How much distress does this cause you?

0
No distress
9.

1

2

3

4

5

Makes me feel guilty when I can’t do the things that are my usual jobs to do.
How much distress does this cause you?

0
No distress
10.

1

2

3

4

5

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

7

8

9
10
Severe distress

Makes me too tired to eat.
How much distress does this cause you?

0
No distress
11.

1

2

3

4

5

Makes me limit my family and social activities.
How much distress does this cause you?

0
No distress
12.

1

2

3

4

5

Makes me feel tired more quickly than typical fatigue.
How much distress does this cause you?

0
No distress

1

2

3

4

5
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Appendix A (Continued)
The fatigue or tiredness I am having causes me distress because it:
13.

makes me feel uncertain about my future.
How much distress does this cause you?

0
No distress
14.

1

2

3

4

5

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

6

7

8

9
10
Severe distress

Makes me feel totally exhausted.
How much distress does this cause you?

0
No distress
15.

1

2

3

4

5

Makes me feel like I am a different person.
How much distress does this cause you?

0
No distress
16.

1

2

3

4

5

Makes me stay at home more.
How much distress does this cause you?

0
No distress
17.

1

2

3

4

5

Makes me feel a loss of control over my life.
How much distress does this cause you?

0
No distress
18.

1

2

3

4

5

Makes it difficult for me to remember things.
How much distress does this cause you?

0
No distress
19.

1

2

3

4

5

Makes me feel as if I have no energy.
How much distress does this cause you?

0
No distress

1

2

3

4

5
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Appendix A (Continued)
The fatigue or tiredness I am having causes me distress because it:
20.

Makes me feel like I am losing interest in things.
How much distress does this cause you?

0
No distress

1

2

3

4

5

6

7

8

9
10
Severe distress

Please circle the number that most describes your fatigue.
No fatigue
Fatigue level now
0 1 2

3

4

5

6

7

Severe fatigue
8 9 10

Worst fatigue level
this past 7 days
Usual fatigue level
for the past 7 days

0

0

1

2

3

4

5

6

7

8

9

1

2

3

4

5

6

7

8

9

10

10

Please circle the one number below that best describes your situation now
KARNOFSKY PERFORMANCE SCALE

100

Normal; no complaints; no evidence of disease

90

Able to carry on normal activity; minor signs of symptoms of disease

80

Normal activity with effort; some sign or symptoms of disease

70

Cares for self; unable to carry on normal activity or do active work

60

Requires occasional assistance, but is able to care for most personal needs

50

Requires considerable assistance and frequent medical care

40

Disabled; requires special care and assistance
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Appendix B: Functional Assessment of Cancer Therapy–Bone Marrow Transplant
(FACT-BMT)

Below is a list of statements that other people with your illness have said are
important. Please circle or mark one number per line to indicate your
response as it applies to the past 7 days.
Not
at all

A
little
bit

Some
what

Quite
a bit

Very
much

I have a lack of energy

0

1

2

3

4

I have nausea

0

1

2

3

4

Because of my physical condition, I have
trouble meeting the needs of my family

0

1

2

3

4

I have pain

0

1

2

3

4

I am bothered by side effects of treatment

0

1

2

3

4

I feel ill

0

1

2

3

4

I am forced to spend time in bed

0

1

2

3

4

Not
at all

A
little
bit

some
what

Quite
a bit

Very
much

I feel close to my friends

0

1

2

3

4

I get emotional support from my family

0

1

2

3

4

I get support from my friends

0

1

2

3

4

My family has accepted my illness

0

1

2

3

4

I am satisfied with family communication
about my illness

0

1

2

3

4

I feel close to my partner (or the person who
is my main support)

0

1

2

3

4

PHYSICAL WELL-BEING

SOCIAL/FAMILY WELLBEING

Regardless of your current level of sexual activity, please answer the following
question. If you prefer not to answer it, please mark this box
and go to the next
section.

I am satisfied with my sex life

0
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Appendix B (Continued)

Please circle or mark one number per line to indicate your response as it
applies to the past 7 days.
Not
at all

A
little
bit

Some
-what

Quite
a bit

Very
much

I feel sad

0

1

2

3

4

I am satisfied with how I am coping with my
illness

0

1

2

3

4

I am losing hope in the fight against my
illness

0

1

2

3

4

I feel nervous

0

1

2

3

4

I worry about dying

0

1

2

3

4

I worry that my condition will get worse

0

1

2

3

4

Not
at all

A
little
bit

Some
-what

Quite
a bit

Very
much

I am able to work (include work at home)

0

1

2

3

4

My work (include work at home) is fulfilling

0

1

2

3

4

I am able to enjoy life

0

1

2

3

4

I have accepted my illness

0

1

2

3

4

I am sleeping well

0

1

2

3

4

I am enjoying the things I usually do for fun

0

1

2

3

4

I am content with the quality of my life right

0

1

2

3

4

EMOTIONAL WELL-BEING

FUNCTIONAL WELL-BEING
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Appendix B (Continued)

Please circle or mark one number per line to indicate your response as it
applies to the past 7 days.
Not
at all

A
little
bit

Some
what

Quite
a bit

Very
much

I am concerned about keeping my job (include
work at home)

0

1

2

3

4

I feel distant from other people

0

1

2

3

4

I worry that the transplant will not work

0

1

2

3

4

The effects of treatment are worse than I had
imagined
I have a good appetite

0

1

2

3

4

0

1

2

3

4

I like the appearance of my body

0

1

2

3

4

I am able to get around by myself

0

1

2

3

4

I get tired easily

0

1

2

3

4

I am interested in sex

0

1

2

3

4

I have concerns about my ability to have
children
I have confidence in my nurse(s)

0

1

2

3

4

0

1

2

3

4

I regret having the bone marrow transplant

0

1

2

3

4

I can remember things

0

1

2

3

4

I am able to concentrate

0

1

2

3

4

I have frequent colds/infections

0

1

2

3

4

My eyesight is blurry

0

1

2

3

4

I am bothered by a change in the way food
t t
I have tremors

0

1

2

3

4

0

1

2

3

4

I have been short of breath

0

1

2

3

4

I am bothered by skin problems (rash, itching)

0

1

2

3

4

I have trouble with my bowels

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

ADDITIONAL CONCERNS

My illness is a personal hardship for my close
family members
The cost of my treatment is a burden on me or
my family
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Appendix C: Demographic Data/Health History Information Form
Part A: Demographic data
1. Age___ (Please, do NOT provide your date of birth)
2. Gender: Male ____ Female ____
3. Ethnicity/Race (check one)
___ American Indian/Alaska Native

___ Arab American

___ Asian American/Pacific Islander

___ Black/African American

___ Caucasian/White/Anglo

___ Hispanic/Latino

___ Other
4. Educational background___________________ (Highest grade completed)
5. Marital status: Single ___ Married ___ Widowed ___ Separated ___ Divorced___
6. Employment status:
___ Self employed ___ Employed outside the house
___ Disability ___no ___ yes, specify: ________________________________

Part B: Health History Information
Underlying Cancer diagnosis: _______________________________________
Type of Transplant received: (Check one)
___ Bone Marrow Transplant ___ Blood/Stem Cell Transplant ___ Cord Blood
___ Allogeneic Transplant (from a donor) ___ Autologous Transplant (from self)
Number of months from Transplant completion ______
Are you in complete or partial remission? Complete ___ Partial___ I don’t know__
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Appendix D: Informed Consent
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Appendix D (Continued)
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Appendix D (Continued)
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Appendix D (Continued)
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Appendix D (Continued)
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Appendix E: Moffitt Cancer Center Scientific Review Committee approval

August 14, 2009

Suzan Abduljawad
H. Lee Moffitt Cancer Center & Research Institute
University of South Florida
12902 Magnolia Drive
Tampa, FL 33612
Dear Ms. Abduljawad:
The Behavioral Subcommittee of the Scientific Review Committee (SRC) has
reviewed your response for your research protocol entitled, “Fatigue Symptom
Distress and Its Relationship with Quality of Life in Adult Stem Cell
Transplant Survivors” (MCC 16029). The revised protocol version dated
08/11/2009 is approved as written for use at the Moffitt Cancer Center pending
approval of the Institutional Review Board (IRB) and satisfaction of institutional
operational and financial review requirements. Please be aware that after you
receive IRB approval, you must request study activation before you commence
any study activities. The Protocol Review and Monitoring System will ensure that
all applicable institutional reviews have been completed. You will then be issued
an activation letter. Upon receipt of the activation letter, you will be able to
conduct your study.
It is your responsibility to ensure that all Moffitt staff (nursing, pharmacy, data
management, etc.) is informed and aware of the details of the project. The
committee encourages the use of in-services for those projects that are complex
or require special attention.
All changes made to protocols approved by the SRC must be submitted to the
Protocol Review and Monitoring System. Changes made to the protocol
document require SRC review and approval. Minor changes (i.e. changes to
personnel, non-scientific changes, changes that do not affect patient
participation) will be expedited through the SRC review process.
If this project is not being managed by the Clinical Trials Office or Clinical
Research Unit, then it is your responsibility to follow through with all requirements
for submission to the IRB. All IRB approvals are required to be documented in
Oncore, and all associated regulatory documentation (signed applications, IRB
approval letters and IRB approved consent forms, etc.) are to be saved in the
appropriate study folder in the e-binders directory at J:\ebinders.
Oncore is the Cancer Center’s mechanism for required submission and review of
materials requiring IRB review as well as items requiring review by the Scientific
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Appendix E (Continued)
Review and Protocol Monitoring Committees. If you are not currently reporting
the necessary research activities, such as patient accrual, changes in procedure,
adverse events and continuing reviews in Oncore, please contact Jeryl Madden,
Oncore Coordinator, at 745-6964 for direction.
Sincerely,

Paul Jacobsen, PhD
Chair, Behavioral Subcommittee
Scientific Review Committee

51

Appendix F: Institutional Review Board Approval
DIVISION OF RESEARCH INTEGRITY AND COMPLIANCE
Institutional Review Boards, FWA No. 00001669
12901 Bruce B. Downs Blvd., MDC035.Tampa, FL 33612-4799
(813) 974-5638FAX (813) 974-5618
September 3, 2009
Suzan Abduljawad
College of Nursing
Tampa FL 33612
RE: Expedited Approval for Initial Review
IRB#: 108313 I
Title: Fatigue Symptom Distress and its Effect on Quality of Life in Adult Stem Cell
Transplant Survivors
Study Approval Period: 08/31/2009 to 08/30/2010
Dear Ms. Abduljawad:
On August 31, 2009, Institutional Review Board (IRB) reviewed and APPROVED the above
protocol for the period indicated above. It was the determination of the IRB that your study
qualified for expedited review based on the federal expedited category number five (5) and
seven (7).
Approval included with the Moffitt Adult Informed Consent Form.
Please note, if applicable, only use the IRB-Approved and stamped consent forms for
participants to sign. The enclosed informed consent/assent documents are valid during the
period indicated by the official, IRB-Approval stamp located on page one of the form. Make
copies from the enclosed original.
Please reference the above IRB protocol number in all correspondence regarding this
protocol with the IRB or the Division of Research Integrity and Compliance. In addition, you
can find the Institutional Review Board (IRB) Quick Reference Guide providing guidelines
and resources to assist you in meeting your responsibilities in the conduction of human
participant research on our website. Please read this guide carefully. It is your responsibility
to conduct this study in accordance with IRB policies and procedures and as approved by the
IRB.
We appreciate your dedication to the ethical conduct of human subject research at the
University of South Florida and your continued commitment to human research protections. If
you have any questions regarding this matter, please call 813-974-2036
Sincerely,

Krista Kutash, Ph.D., Chairperson
USF Institutional Review Board
Cc: Various Menzel/cd, USF IRB Professional Staff
Susan McMillan PhD
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